A real-world retrospective study found that adding GLP-1 receptor agonists to hormone therapy may reduce endometrial cancer risk in women with benign uterine or endometrial hyperplasia. This study was...
Researchers evaluated the safety and efficacy of dolutegravir plus lamivudine in treatment-naive individuals with HIV without baseline resistance testing.
A study assesses whether the dual sodium–glucose co-transporter (SGLT) 1/2 inhibitor sotagliflozin reduces ischemic events in diabetes and kidney disease.
A phase 3 trial subgroup analysis found that adding pembrolizumab to adjuvant chemotherapy may improve disease-free survival in patients with mismatch repair-deficient endometrial cancer, a population at...
In this respiratory disease roundup, experts examine the rising cases of human metapneumovirus in China, new research on COVID-19’s long-term effects on kidney function, the effectiveness of...
A randomized trial evaluated the effectiveness of nonopioid versus opioid analgesics for managing pain after mandibular third-molar extraction surgery.
A decade-long follow-up of a landmark trial examining survival outcomes in patients with advanced melanoma treated with nivolumab plus ipilimumab, nivolumab monotherapy, or ipilimumab monotherapy, provides...
A recent phase 3 study found that venetoclax-obinutuzumab improves progression-free survival and quality of life compared with chlorambucil-obinutuzumab in patients with untreated chronic lymphocytic...
Plozasiran, a first-in-class RNA interference therapeutic, reduced triglycerides by 80% and lowered the risk of acute pancreatitis by 83% in patients with familial chylomicronemia syndrome, earning FDA...
A recent phase 3b long-term extension study assessed the safety and efficacy of deucravacitinib over 2 years in patients with moderate-to-severe plaque psoriasis.
